HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $63
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $61 to $63.

July 18, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals' price target has been raised from $61 to $63 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Mirum Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100